Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Hansa Biopharma
  4. Hansa Biopharma — Juni 2024

Hansa Biopharma — Juni 2024

Planlagt Fastgjort Låst Flyttet Hansa Biopharma
63 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #39

    Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

    https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys?_ga=2.70363152.1041565330.1718893358-1568418063.1716906982

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #40

      Blev godkendt!

      1 Reply Last reply
      0
      • exitnuE Offline
        exitnuE Offline
        exitnu
        wrote on sidst redigeret af
        #41

        – FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients

        – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients

        – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #42

          Godmorgen 🙂

          1 Reply Last reply
          0
          • L Offline
            L Offline
            LP90
            wrote on sidst redigeret af
            #43

            Godmorgen 🙂 super nyhed exitnu

            1 Reply Last reply
            0
            • exitnuE Offline
              exitnuE Offline
              exitnu
              wrote on sidst redigeret af
              #44

              God morgen 🙂

              1 Reply Last reply
              0
              • SEACOPS Offline
                SEACOPS Offline
                SEACOP
                wrote on sidst redigeret af
                #45

                @exitnu. Tak for alle dine indlæg gennem tiden. I dag med
                et af de absolut bedste 🙂

                1 Reply Last reply
                0
                • exitnuE Offline
                  exitnuE Offline
                  exitnu
                  wrote on sidst redigeret af
                  #46

                  Mange tak til ALLE.

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #47

                    Kursudviklingen for Sarepta Therapeutics efter børstid kommer ikke til at blive afspejlet direkte, da DMD-aftalen kun udgør en mindre del/værdi af Hansa Biopharmas portefølje, som eksempelvis nævnt i en tidligere analyse fra Penser Access (nu overtaget af Carnegie).

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #48

                      Sarepta Therapeutics surges 36% after-hours following expanded FDA approval

                      Just a moment...

                      favicon

                      (www.investing.com)

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #49

                        ... vi må se på mandag, hvordan det går 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #50

                          Det bliver spændende. 🙂

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #51

                            Sarepta's DMD gene therapy secures much-sought-after label expansion https://firstwordpharma.com/story/5868924

                            1 Reply Last reply
                            0
                            • exitnuE Offline
                              exitnuE Offline
                              exitnu
                              wrote on sidst redigeret af
                              #52

                              Kursudviklingen for Sarepta Therapeutics er ganske pæn i US i dag fredag 🙂

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #53

                                Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

                                Link Preview Image
                                Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval

                                Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy.

                                favicon

                                Investor's Business Daily (www.investors.com)

                                "The approval expands the market for Elevidys by more than tenfold, Leerink Partners analyst Joseph Schwartz said. Under the original approval, about 7% of patients were eligible for the gene therapy. Now, about 80% are eligible, he said in a report."

                                1 Reply Last reply
                                0
                                • Z Offline
                                  Z Offline
                                  Zambo
                                  wrote on sidst redigeret af
                                  #54

                                  Er det til hver behandling Sarepta bruger
                                  imlifidase, eller kun en mulighed at bruge?

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #55

                                    De bruger det ikke endnu, du har svaret her: https://clinicaltrials.gov/study/NCT06241950?term=Sarepta&aggFilters=status:act&rank=6&tab=history

                                    1 Reply Last reply
                                    0
                                    • Z Offline
                                      Z Offline
                                      Zambo
                                      wrote on sidst redigeret af
                                      #56

                                      Tak, også det som jeg havde forstået:) så ser vi vel ikke den store stigning på mandag pga Sarepta godkendelse?:)

                                      1 Reply Last reply
                                      0
                                      • M Offline
                                        M Offline
                                        MBCruise
                                        wrote on sidst redigeret af
                                        #57

                                        Det er ca. 14% af patienter som er potentielle. Ca. 3-400 nyfødte drengebørn i US om året som har DMD. Imlifidase er endnu ikke godkendt i US. Roche står for udrulning af Sareptas genterapi i Europ. Hansa modtager ca 10% i fee,
                                        hvilket svarer til ca.

                                        1 Reply Last reply
                                        0
                                        • M Offline
                                          M Offline
                                          MBCruise
                                          wrote on sidst redigeret af
                                          #58
                                          • salg af Imlifidase, hvilket vel svarer til ca. DKK 4mio. pr. solgt behandling. Og så er der milestones
                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper